Your browser doesn't support javascript.
loading
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Kaminska, Kamila; Akrap, Nina; Staaf, Johan; Alves, Carla L; Ehinger, Anna; Ebbesson, Anna; Hedenfalk, Ingrid; Beumers, Lukas; Veerla, Srinivas; Harbst, Katja; Ehmsen, Sidse; Borgquist, Signe; Borg, Åke; Pérez-Fidalgo, Alejandro; Ditzel, Henrik J; Bosch, Ana; Honeth, Gabriella.
Affiliation
  • Kaminska K; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Akrap N; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Staaf J; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Alves CL; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Ehinger A; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Ebbesson A; Division of Clinical Genetics and Pathology, Department of Laboratory Medicine, Skåne University Hospital, Lund, Sweden.
  • Hedenfalk I; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Beumers L; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Veerla S; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Harbst K; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Ehmsen S; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Borgquist S; Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Borg Å; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Pérez-Fidalgo A; Aarhus University Hospital, Aarhus, Denmark.
  • Ditzel HJ; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Bosch A; INCLIVA Biomedical Research Institute, Valencia, Spain.
  • Honeth G; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Breast Cancer Res ; 23(1): 26, 2021 02 18.
Article in En | MEDLINE | ID: mdl-33602273
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Estrogen / Cyclin-Dependent Kinases / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Estrogen Receptor Antagonists / Fulvestrant Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Estrogen / Cyclin-Dependent Kinases / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Estrogen Receptor Antagonists / Fulvestrant Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Country of publication: